CRISPR-enhanced assessment of variants of unknown significance nominates oncology therapeutic targets and drug repositioning opportunities
TL;DR
CRISPR-VUS combines dependency-based rare-variant discovery with evidence-guided prioritisation to nominate candidate drivers, therapeutic targets and drug-repositioning hypotheses to nominate candidate drivers, therapeutic targets and drug-repositioning hypotheses.
Abstract
Interpreting infrequent somatic variants remains a challenge in cancer genomics. We developed CRISPR-VUS, a framework that uses public Cancer Dependency Map data to identify Dependency-Associated Mutations (DAMs) - variants linked to increased host-gene dependency - with resolution extending to singleton events. Analysis of 977 cell lines across 36 cancer types identified 2,376 DAMs in 1,383 genes, including 1,260 not established as cancer drivers. DAM-bearing genes converge on oncogenic networks, while recurrence in histology-matched tumours, functional-impact predictions, tractability and pharmacological associations enable systematic prioritisation. Prime editing showed that the prioritised NSCLC-specific RTN4IP1-A80T DAM conferred a significant competitive growth advantage in a lung epithelial model, nominating a candidate driver allele. Exploratory pharmacological testing showed a greater maximal response to istaroxime in ATP1B3-I189M-bearing than in ATP1B3-wild-type cells. CRISPR-VUS combines dependency-based rare-variant discovery with evidence-guided prioritisation to nominate candidate drivers, therapeutic targets and drug-repositioning hypotheses. Interactive results are available at https://vus-portal.fht.org/.
